Quarterly report [Sections 13 or 15(d)]

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.25.1
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Product Information [Line Items]    
Net Revenue $ 1,853,597 $ 2,406,391
Total operating loss (2,627,139) (1,945,230)
Non-operating income (expense), net (24,583) (12,913)
Net loss before income taxes (2,651,722) (1,958,143)
Income tax expense (8,695) (3,672)
Net loss (2,660,417) (1,961,815)
Diagnostic R&D [Member]    
Product Information [Line Items]    
Net Revenue 2,885
Total operating loss (505,739) (442,599)
Laboratory Services [Member]    
Product Information [Line Items]    
Net Revenue 1,853,597 2,403,506
Total operating loss (2,267,656) (2,736,999)
General Corporate Activities [Member]    
Product Information [Line Items]    
Total operating loss $ (1,707,341) $ (1,172,023)